8-K: Kintara Therapeutics Believes it Regained Nasdaq Compliance After $8.1 Million Capital Raise

Kintara Therapeutics believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement after raising $8.1 million through an at-the-market offering.

Summary

• Kintara Therapeutics was previously notified by Nasdaq that it did not meet the minimum stockholders' equity requirement for continued listing.
• The company submitted a plan to regain compliance and was granted an extension until March 18, 2024.
• Kintara raised $8.1 million through the sale of common stock between January 1, 2024 and February 23, 2024.
• The company believes that this capital raise has brought its stockholders' equity above the required $2.5 million threshold.
• Kintara is now awaiting a compliance determination from Nasdaq.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has taken steps to address a critical compliance issue and has raised significant capital. However, the risk of delisting remains until a positive determination is received from Nasdaq.

Positives

• Kintara successfully raised $8.1 million through an at-the-market offering.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement.
• The company has taken proactive steps to address the compliance issue.

Negatives

• Kintara was previously non-compliant with Nasdaq's minimum stockholders' equity requirement.
• The company had a negative stockholders' equity of $164,000 as of December 31, 2023.
• There is a risk of delisting if the company fails to maintain compliance.

Risks

• There is a risk of delisting if Kintara does not receive a positive compliance determination from Nasdaq.
• The company's future is dependent on maintaining compliance with Nasdaq listing requirements.
• The company's financial position was previously weak with negative stockholders' equity.

Future Outlook

The company is awaiting a compliance determination from Nasdaq and must maintain compliance to avoid delisting.

Management Comments

• The company believes as of the date of the filing that it has stockholders equity above the $2.5 million Stockholders Equity Requirement and is awaiting a compliance determination from Nasdaq.

Industry Context

This announcement is specific to Kintara's compliance with Nasdaq listing requirements, which is a common issue for smaller biotech companies. Many companies in the sector face challenges in maintaining sufficient equity to meet listing requirements.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance due to the high costs of research and development and the long timeframes to commercialization.
• Companies like Kintara often rely on capital raises to maintain operations and meet listing requirements.
• The $2.5 million minimum stockholders' equity requirement is a standard benchmark for Nasdaq Capital Market listings.

Stakeholder Impact

• Shareholders are impacted by the risk of delisting and the potential for share dilution from the capital raise.
• Employees are impacted by the uncertainty surrounding the company's listing status.
• Creditors are impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• Kintara is awaiting a compliance determination from Nasdaq.
• The company must file its periodic report for the quarter ending March 31, 2024, to evidence compliance.

Key Dates

Keywords

Nasdaq compliance, stockholders equity, capital raise, at-the-market offering, delisting, KTRA